NCT02086682

Brief Summary

The introduction of unfractionated heparin (UFH), which prevents clotting of the extracorporal circuit, was one of the key advances that led to the rapid development and expansion of hemodialysis services. However, anticoagulation during hemodialysis of the patient at high risk for bleeding remains a frequently encountered problem in both inpatient and outpatient dialysis practice. Streamline bloodlines are designed to eliminate blood-air contact. This is thought to help reduce heparin use and decrease clotting rates. The goal of this study was to prospectively examine impact of the Streamline airless blood tubing set, in an inpatient setting, on dialysis circuit clotting rates, anticoagulation use, and dialysis efficiency.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
338

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 10, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 13, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
4 years until next milestone

Results Posted

Study results publicly available

July 15, 2019

Completed
Last Updated

July 15, 2019

Status Verified

May 1, 2019

Enrollment Period

1.6 years

First QC Date

March 10, 2014

Results QC Date

September 13, 2017

Last Update Submit

May 1, 2019

Conditions

Keywords

hemodialysisdialysisrenal dialysisclottingcoagulationblood lines

Outcome Measures

Primary Outcomes (1)

  • Clotting of Extracorporeal Dialysis Circuit

    Each dialysis session was prospectively observed for Clotting of Extracorporeal Dialysis Circuit. Events were defined as interruption of hemodialysis session, loss of the hemodialysis circuit, or inability to return blood to the patient upon rinse back.

    During the dialysis session, approximately 211 minutes

Study Arms (2)

General Care Cohort

The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.

Critical Care Cohort

The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit or the ICU during the recruitment period.

You may qualify if:

  • All adult non-pregnant patients requiring inpatient hemodialysis at our center during the recruitment period until the target sample of dialysis sessions (n=1200) was reached.

You may not qualify if:

  • Pregnant females
  • Children

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic Hospital, Saint Marys Campus

Rochester, Minnesota, 55902, United States

Location

Related Publications (1)

  • Safadi S, Albright RC Jr, Dillon JJ, Williams AW, Alahdab F, Brown JK, Severson AL, Kremers WK, Ryan MA, Hogan MC. Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice. Kidney Int Rep. 2017 Mar 16;2(4):695-704. doi: 10.1016/j.ekir.2017.03.003. eCollection 2017 Jul.

Related Links

MeSH Terms

Conditions

Blood Coagulation DisordersThrombosis

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Results Point of Contact

Title
Dr. Marie Hogan
Organization
Mayo Clinic

Study Officials

  • Marie C. Hogan, M.D., Ph.D.

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor of Medicine

Study Record Dates

First Submitted

March 10, 2014

First Posted

March 13, 2014

Study Start

January 1, 2014

Primary Completion

August 1, 2015

Study Completion

August 1, 2015

Last Updated

July 15, 2019

Results First Posted

July 15, 2019

Record last verified: 2019-05

Locations